[{"address1": "Wallstrasse 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "fax": "49 89 2153 90351", "website": "https://www.atai.life", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.", "fullTimeEmployees": 83, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder & CEO", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 793650, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 494232, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frank  Stegert", "age": 43, "title": "Vice President of Investment & Venture Management", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sahil V. Kirpekar M.D.", "age": 38, "title": "Chief Business Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.27, "open": 2.27, "dayLow": 2.26, "dayHigh": 2.48, "regularMarketPreviousClose": 2.27, "regularMarketOpen": 2.27, "regularMarketDayLow": 2.26, "regularMarketDayHigh": 2.48, "beta": 1.227, "forwardPE": -3.3989978, "volume": 6578238, "regularMarketVolume": 6578238, "averageVolume": 2438701, "averageVolume10days": 6280030, "averageDailyVolume10Day": 6280030, "bid": 2.26, "ask": 2.44, "bidSize": 5600, "askSize": 5700, "marketCap": 385944576, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 2.85, "priceToSalesTrailing12Months": 1165.9957, "fiftyDayAverage": 1.6008, "twoHundredDayAverage": 1.46, "currency": "USD", "enterpriseValue": 326828512, "floatShares": 128607112, "sharesOutstanding": 167802000, "sharesShort": 11307134, "sharesShortPriorMonth": 10743811, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0674, "heldPercentInsiders": 0.10018, "heldPercentInstitutions": 0.28052, "shortRatio": 6.49, "shortPercentOfFloat": 0.0883, "impliedSharesOutstanding": 167802000, "bookValue": 0.868, "priceToBook": 2.6497695, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -128603000, "trailingEps": -0.8, "forwardEps": -0.68, "enterpriseToRevenue": 987.397, "enterpriseToEbitda": -3.154, "52WeekChange": 0.12935328, "SandP52WeekChange": 0.22903383, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ATAI", "underlyingSymbol": "ATAI", "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "firstTradeDateEpochUtc": 1624023000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "8699f3bf-7398-34d0-b0ba-129948e2583d", "messageBoardId": "finmb_710359021", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.3, "targetHighPrice": 11.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 85920000, "totalCashPerShare": 0.512, "ebitda": -103638000, "totalDebt": 26207000, "quickRatio": 4.438, "currentRatio": 5.807, "totalRevenue": 331000, "debtToEquity": 17.911, "revenuePerShare": 0.002, "returnOnAssets": -0.25702, "returnOnEquity": -0.62773, "grossProfits": 331000, "freeCashflow": -65382248, "operatingCashflow": -80104000, "revenueGrowth": -0.54, "grossMargins": 1.0, "operatingMargins": -565.05, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]